| Name | Title | Contact Details |
|---|
Kudo Biotechnology is a global CDMO, providing world-class, end-to-end mRNA manufacturing solutions, all under one roof. Kudo has state-of the-art clinical GMP manufacturing facilities and labs in Boston, China & Singapore, making pDNA, mRNA and LNP. Kudo Bio differentiates by being a one-stop stop for all your mRNA manufacturing needs, by streamlining the process, removing bottlenecks and ensuring ease in your CMC. Our performance matches and surpasses industry-leading yields & efficiencies across all stages of the process. Our speed of 6.5 months from sequence to GMP mRNA-LNP exceeds industry platinum standards, and our quality is superior to competitors while maintaining full compliance with global regulatory requirements. Kudo Bio has a track record of accomplishing end-to-end GMP manufacturing with products entering the clinic, and successfully completing multiple batches of process validation after international technology transfer. We have an industry-leading manufacturing cGMP facility with capacity to make up to 50 GMP batches annually, with deep technology partnerships enabling access to scale-up expertise & production know-how. Finally a comprehensive quality management system with QA/QC capabilities which meet major regulatory agencies compliance requirements is paramount to delivering products to customers around the world.
Bactrin International is a Belgrade, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SkinMedica, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.
AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales.